Source comparison
Tesamorelin + Ipamorelin Blend Biomarkers: Clinical Comparison
IGF-1 115–307 ng/mL (age-dependent) Upper-normal for age (200–280 ng/mL for adults 30–50) Growth hormone response and anabolic signaling strength Increase dose or check ipamorelin purity. Low IGF-1 suggests poor GH pulse amplitude IGF-1/IGFBP-3 Ratio 0.15–0.30
This comparison does not assign a generated winner or score.
- IGF-1
- 115–307 ng/mL (age-dependent)
- Upper-normal for age (200–280 ng/mL for adults 30–50)
- Growth hormone response and anabolic signaling strength
- Increase dose or check ipamorelin purity. Low IGF-1 suggests poor GH pulse amplitude
- IGF-1/IGFBP-3 Ratio
- 0.15–0.30 (molar ratio)
- ≥0.25
- Bioavailable IGF-1. Not just production
- Improve insulin sensitivity to lower IGFBP-3; consider caloric restriction
- Fasting Insulin
- 2–10 µIU/mL
- <7 µIU/mL
- Insulin resistance blocking lipolysis
- Add metformin or berberine; reduce refined carbohydrates
- HOMA-IR
- <1.0 (optimal), <2.0 (acceptable)
- <1.5
- Insulin sensitivity. Gate for fat mobilization
- Structured carbohydrate restriction; consider GLP-1 co-administration
- Visceral Adipose Tissue (DEXA)
- Gender/age-specific
- 10–15% reduction over 12 weeks
- The primary outcome tesamorelin targets
- Reassess dosing, timing, and metabolic cofactors if <5% at 12 weeks
- Morning Cortisol
- 6–23 µg/dL
- 10–16 µg/dL
- Chronic stress blocking fat oxidation
- Address sleep, reduce training volume, consider adaptogenic support